The use of neural networks will enable the design of personalized cancer vaccines in 30 minutes to 1 hour. To train artificial intelligence, an experimental database of about 40-50 thousand tumors with antigen compatibility definitions is needed. These will be processed into proteins or RNA in patients. This will allow AI to determine whether a specific combination can be used for an individual. Preclinical studies of the cancer vaccine have shown that it can suppress tumor development and possibly prevent metastasis. The first individuals to receive the new cancer vaccine in clinical trials may include patients with melanoma and small cell lung cancer. The vaccine was developed in collaboration with several research teams, including the Gamaleya Center, the Moscow P. A. Herzen Oncology Institute, and the N. N. Blokhin National Cancer Research Center. Previously, Andrei Kaprin, Chief Oncologist of the Russian Ministry of Health and Director General of the National Radiology Center, stated that preclinical trials have already been completed.